지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2010.6
- 수록면
- 350 - 356 (7page)
이용수
초록· 키워드
오류제보하기
Purpose: The platinum-based modified FOLFOX-6 has been reported as an acceptable chemotherapeutic regimen in treatment of advanced gastric cancer patients. The response rate and drug-induced toxicity of platinum-based chemoagents is different according to several gene polymorphism such as ERCC1, XRCC1 and GSTP1 genes, which were related with therapeutic mechanisms. We aimed to evaluate the effect of gene polymorphism and determine the possibility as prediction factor for responsibility in advanced and recurrent gastric cancer patients treated with modified FOLFOX-6 regimen.
Methods: This study was conducted with 55 patients. We sampled 20 ml of peripheral blood to isolate DNA from lymphocytes, and identified genotypes of 3 genes (ERCC1, XRCC1, GSTP1) by PCR-RFL of extracted DNA. Based on medical records, retrospective analysis was made on the patients’ clinical characteristics.
Results: The overall response rate to modified FOLFOX-6 was 40.0% (22/55). In polymorphism of ERCC1 C8092A, the wild type (CC) showed a statistically significantly lower response rates to chemoagents than the mutant type (CA/AA). In the subtypes of ERCC1 C118T, however, the wild type (CC) showed statistically significantly lower hematological toxicity than the mutant type (CA/AA). But, there was no statistically significance in survival analysis.
Conclusion: We suggest that ERCC1 gene polymorphism is clinically more adequate as a feasible factor for predicting the response rate and toxicity of modified FOLFOX-6 regimen in gastric cancer patients.
Methods: This study was conducted with 55 patients. We sampled 20 ml of peripheral blood to isolate DNA from lymphocytes, and identified genotypes of 3 genes (ERCC1, XRCC1, GSTP1) by PCR-RFL of extracted DNA. Based on medical records, retrospective analysis was made on the patients’ clinical characteristics.
Results: The overall response rate to modified FOLFOX-6 was 40.0% (22/55). In polymorphism of ERCC1 C8092A, the wild type (CC) showed a statistically significantly lower response rates to chemoagents than the mutant type (CA/AA). In the subtypes of ERCC1 C118T, however, the wild type (CC) showed statistically significantly lower hematological toxicity than the mutant type (CA/AA). But, there was no statistically significance in survival analysis.
Conclusion: We suggest that ERCC1 gene polymorphism is clinically more adequate as a feasible factor for predicting the response rate and toxicity of modified FOLFOX-6 regimen in gastric cancer patients.
목차
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
참고문헌 (19)
참고문헌 신청
1. [보고서] - Ministry of Health and Welfare / 2003 / 2002 Annual Report of the Korea Central Cancer Registry: Based on Registered Data from 139 Hospitals
2. [학술지(정기간행물)] - Louvet C / 2002 / Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients / J Clin Oncol 20 : 4543 ~ 4548
3. [학술지(정기간행물)] - Al-Batran SE / 2004 / Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer / J Clin Oncol 22 : 658 ~ 663
4. [학술지(정기간행물)] - Chao Y / 2004 / Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer / Br J Cancer 91 : 453 ~ 458
5. [학술지(정기간행물)] - Evans WE / 1999 / Pharmacogenomics: translating functional genomics into rational therapeutics / Science 286 : 487 ~ 491
2. [학술지(정기간행물)] - Louvet C / 2002 / Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients / J Clin Oncol 20 : 4543 ~ 4548
3. [학술지(정기간행물)] - Al-Batran SE / 2004 / Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer / J Clin Oncol 22 : 658 ~ 663
4. [학술지(정기간행물)] - Chao Y / 2004 / Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer / Br J Cancer 91 : 453 ~ 458
5. [학술지(정기간행물)] - Evans WE / 1999 / Pharmacogenomics: translating functional genomics into rational therapeutics / Science 286 : 487 ~ 491
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Investigating the Frequency of the ERCC1 Gene C8092A Polymorphism in Iranian Patients with Advanced Gastric Cancer
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
GSTP1, ERCC1 and ERCC2 Polymorphisms, Expression and Clinical Outcome of Oxaliplatin-based Adjuvant Chemotherapy in Colorectal Cancer in Chinese Population
Asian Pacific journal of cancer prevention : APJCP
2012 .01
-
Glutathione S-transferase P1 and DNA Polymorphisms with the Response to Chemotherapy and the Prognosis of Bone Tumor
Asian Pacific journal of cancer prevention : APJCP
2012 .01
-
Increased ERCC Expression Correlates w ith Improved Outcome of Patients T reated w ith C isplatin as an A djuvant Therapy for Curatively Resected Gastric Cancer
Cancer Research and Treatment
2006 .01
-
ERCC1 Expression Does Not Predict Survival and Treatment Response in Advanced Stage Non-Small Cell Lung Cancer Cases Treated with Platinum Based Chemotherapy
Asian Pacific journal of cancer prevention : APJCP
2013 .01
-
The ERCC1 C118T Polymorphism Predicts Clinical Outcomes of Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy: a Meta-analysis Based on 22 Studies
Asian Pacific journal of cancer prevention : APJCP
2014 .01
-
ERCC1 Expression Can Predict Response to Platinum-Based Induction Chemotherapy in Head and Neck Cancer Cases
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Predictive Value of the ERCC1 Expression for Treatment Response and Survival in Advanced Gastric Cancer Patients Receiving Cisplatin-based First-line Chemotherapy
Cancer Research and Treatment
2010 .01
-
Genetic Association between ERCC5 rs17655 Polymorphism and Colorectal Cancer Risk: Evidence Based on a Meta-analysis
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Association of Four ERCC1 and ERCC2 SNPs with Survival of Bone Tumour Patients
Asian Pacific journal of cancer prevention : APJCP
2012 .01
-
The DNA Repair Gene ERCC6 rs1917799 Polymorphism is Associated with Gastric Cancer Risk in Chinese
Asian Pacific journal of cancer prevention : APJCP
2013 .01
-
Nucleotide Excision Repair Gene ERCC2 and ERCC5 Variants Increase Risk of Uterine Cervical Cancer
Cancer Research and Treatment
2016 .01
-
Meta-analysis of Excision Repair Cross-complementation Group 1 (ERCC1) Association with Response to Platinum-based Chemotherapy in Ovarian Cancer
Asian Pacific journal of cancer prevention : APJCP
2013 .01
-
Associations of ERCC4 rs1800067 Polymorphism with Cancer Risk: an Updated Meta-analysis
Asian Pacific journal of cancer prevention : APJCP
2014 .01
-
Polymorphisms in DNA Repair Genes and Risk of Glioma and Meningioma
Asian Pacific journal of cancer prevention : APJCP
2013 .01
-
ERCC1 as a Biological Marker Guiding Management in Malignant Pleural Mesothelioma
Asian Pacific journal of cancer prevention : APJCP
2014 .01
-
Single Nucleotide Polymorphisms in the NER Pathway and Clinical Outcome of Patients with Bone Malignant Tumor
Asian Pacific journal of cancer prevention : APJCP
2013 .01
-
Expression of ERCC1, MSH2 and PARP1 in Non-small Cell Lung Cancer and Prognostic Value in Patients Treated with Platinum-based Chemotherapy
Asian Pacific journal of cancer prevention : APJCP
2014 .01
-
비소세포 폐암환자의 객담 내 ERCC1 발현정도와 cisplatin 복합화학요법 후 치료반응
Tuberculosis and Respiratory Diseases
2006 .01
-
Combination of TRAP1 and ERCC1 Expression Predicts Clinical Outcomes in Metastatic Colorectal Cancer Treated with Oxaliplatin/5-Fluorouracil
Cancer Research and Treatment
2014 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0